Cheung A N, Ngan H Y, Collins R J, Wong Y L
Department of Pathology, University of Hong Kong.
J Clin Pathol. 1994 Jul;47(7):601-4. doi: 10.1136/jcp.47.7.601.
To assess the role of Ki67 immunoreactivity in predicting the clinical progress of hydatidiform mole.
Tissue from 87 hydatidiform moles, 11 normal first trimester placentas, 11 normal term placentas and 17 spontaneous abortions were examined for expression of Ki67 antigen, using the monoclonal antibody MIB1.
Ki67 immunoreactivity was significantly higher in the tissue from normal first trimester placentas than in that from normal term placentas and spontaneous abortions. Among the 87 patients with hydatidiform moles studied, 20 developed persistent gestational trophoblastic disease and required subsequent treatment. There was no statistically significant difference in the Ki67 index between the 20 patients who developed persistent disease and those who did not.
Hydatidiform moles which give rise to persistent trophoblastic disease do not have a higher proliferative rate than those which do not. The Ki67 index is not useful for predicting the prognosis of molar pregnancies.
评估Ki67免疫反应性在预测葡萄胎临床进展中的作用。
使用单克隆抗体MIB1检测87例葡萄胎、11例正常早孕胎盘、11例足月正常胎盘和17例自然流产组织中Ki67抗原的表达。
正常早孕胎盘组织中的Ki67免疫反应性显著高于足月正常胎盘和自然流产组织。在研究的87例葡萄胎患者中，20例发生持续性妊娠滋养细胞疾病并需要后续治疗。发生持续性疾病的20例患者与未发生持续性疾病的患者之间，Ki67指数无统计学显著差异。
发生持续性滋养细胞疾病的葡萄胎的增殖率并不高于未发生该疾病的葡萄胎。Ki67指数对预测葡萄胎妊娠的预后并无帮助。
